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Background: SAMHD1 degrades deoxyribonucleotides (dNTPs), suppressing viral DNA synthesis in macrophages.
Recently, viral protein X (Vpx) of HIV-2/SIVsm was shown to target SAMHD1 for proteosomal degradation and led
to elevation of dNTP levels, which in turn accelerated proviral DNA synthesis of lentiviruses in macrophages.
Results: We investigated both time-dependent and quantitative interplays between SAMHD1 level and dNTP
concentrations during multiple exposures of Vpx in macrophages. The following were observed. First, SAMHD1
level was rapidly reduced by Vpx + VLP to undetectable levels by Western blot analysis. Recovery of SAMHD1 was
very slow with less than 3% of the normal macrophage level detected at day 6 post Vpx treatment and only ~30%
recovered at day 14. Second, dGTP, dCTP and dTTP levels peaked at day 1 post Vpx treatment, whereas dATP
peaked at day 2. However, all dNTPs rapidly decreased starting at day 3, while SAMHD1 level was below the level
of detection. Third, when Vpx pretreated macrophages were re-exposed to a second Vpx treatment at day 7, we
observed dNTP elevation that had faster kinetics than the first Vpx + VLP treatment. Moreover, we performed a short
kinetic analysis of the second Vpx treatment to find that dATP and dGTP levels peaked at 8 hours post secondary
VLP treatment. dGTP peak was consistently higher than the primary, whereas peak dATP concentration was basically
equivalent to the first Vpx + VLP treatment. Lastly, HIV-1 replication kinetics were faster in macrophages treated after
the secondary Vpx treatments when compared to the initial single Vpx treatment.
Conclusion: This study reveals that a very low level of SAMHD1 sufficiently modulates the normally low dNTP levels
in macrophages and proposes potential diverse mechanisms of Vpx-mediated dNTP regulation in macrophages.
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Sterile alpha motif (SAM) and histidine/aspartic acid
(HD) domain protein 1 (SAMHD1) has been linked to
Aicardi-Goutières Syndrome, which is a rare autoimmune
disease [1]. In addition to its role in autoimmunity [2-4],
SAMHD1 has been studied in the context of antiviral
response [1,5-12] and genomic stability [2,13]. Several
groups have now shown that SAMHD1 is found in all
cell types and localizes to the nucleus [5,10,14-19].* Correspondence: baek.kim@emory.edu
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article, unless otherwise stated.Recent evidence indicates that SAMHD1 has at least
two different cellular functions. First, SAMHD1 was
shown to have deoxyribonucleoside triphosphate (dNTP)
phosphohydrolase activity [20,21], suggesting it is a host
antiviral restriction factor to limit replication of retroviral
and DNA containing viruses by depleting cellular dNTPs
in viral non-dividing target cell types [22-25]. Recently,
both biochemical and structural evidence indicated that
SAMHD1 forms a tetramer as the active dNTP phospho-
hydrolase complex [26-29]. When dNTPs bind in the
active site, the tetramer is formed, and the tetramer
was suggested to be long-lived in the cell [30]. SAMHD1
tetramer could maintain the cellular dNTP concentrations
at a very low level outside the S phase of the cell cycle.
Second, SAMHD1 was shown to have nuclease activity.
The nuclease activity was localized to the HD domain
of SAMHD1 [31]. Both single-stranded DNA and RNAentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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[29,32].
Regulation of SAMHD1 occurs by three mechanisms.
First, promoter methylation was shown to inhibit tran-
scription [33], leading to a reduction in SMAHD1 levels.
Second, SAMHD1 is regulated during S phase [34,35],
being targeted for degradation. Third, SAMHD1 phos-
phorylation at T592 [35] was shown to regulate its anti-
viral activity but not dNTP phosphohydrolase activity
[11]. Importantly, White et al. have shown non-dividing
cells do not phosphorylate SAMHD1 at T592, whereas
cycling cells do [11].
HIV-2 and some SIV strains encode for the accessory
viral protein X (Vpx). It has the ability to target human
SAMHD1 to the proteasome for degradation by DCAF1-
E3-ubiquitin ligase [36-38]. Vpx interacts with the C-
terminus of SAMHD1 in order to facilitate this degradation
[14,39,40]. Recent reports have examined the acute kinetics
of Vpx-mediated SAMHD1 degradation in myeloid cells
and the enhancement of HIV-1 infection after Vpx treat-
ment [8,41]. Further, we have reported in detail the
acute effects of Vpx-mediated SAMHD1 degradation in
monocyte-derived macrophages (MDMs) [42], which led
to increased dNTP levels followed by enhancement of
proviral DNA synthesis and transduction of MDMs.
In this report we performed an extensive kinetic and
quantitative analysis examining the prolonged changes
in dNTP concentrations and SAMHD1 levels over 14 days
in primary human MDMs. In addition, we treated macro-
phages either with a single or dual VLP treatments, i.e.
after the single Vpx + VLP treatment that kept SAMHD1
levels reduced by Western blots, and then measured
dNTP levels and cellular nucleotide metabolites. While
SAMHD1 remained very low, a second Vpx + VLP treat-
ment promoted a rapid and robust increase in dNTPs.
Collectively these data suggest that a very low level of
SAMHD1 can dramatically modulate the dNTP concen-
trations in primary human MDMs.
Results
Monitoring the long-term kinetics of SAMHD1 levels and
dNTP concentrations in human primary monocyte-derived
macrophages
We previously reported the acute effects of Vpx contain-
ing virus-like particles (VLP) treatment on human primary
MDMs out to 48 h [42] and observed that the dGTP levels
had peaked at day 1 and already started to decline at day 2
post Vpx treatment, while the SAMHD1 protein remained
undetectable by western blot analysis. Many investigators
have reported the effects of brief Vpx exposures in various
cell types [8,18,19,41-43]. In this study, we investigated
the recovery of SAMHD1 and changes in all four dNTP
concentrations over 14 days in order to better understand
cellular biology of SAMHD1 in primary human MDMtreated with Vpx- or Vpx + VLP. As shown in Figure 1A,
SAMHD1 remained undetectable under the immunoblot
conditions described in previous studies until day 5, which
is consistent with the long half-life of Vpx [6]. Vpx has
a 30 h half-life, suggesting it would be decayed by day 5
after VLP + VLP treatment. Quantitative analysis for
the SAMHD1 protein level (20 μg) from three donors
(Figure 1B) revealed that at day 6, the SAMHD1 level
was less than 3% of the normal endogenous SAMHD1
level found in MDMs, which was confirmed by loading
3× (60 μg) the amount of protein at day 6 (Figure 1C).
Importantly, SAMHD1 began to recover to a consistently
detectable level around day 7 and continued to recover to
only 30% expression at day 14 (Figure 1A). These data
indicate that a single treatment of Vpx + VLP can induce a
very prolonged phase of SAMHD1 reduction in MDMs
followed by a slow recovery of protein.
Next, we employing our highly sensitive HIV-1 RT-
based dNTP assay [44] to examine the effects on dNTP
pools after Vpx-mediated SAMHD1 degradation in the
same MDM donors used in Figure 1B. As shown in
Figures 1D-G, increases in all four dNTPs were clearly
detected after Vpx + VLP treatment in MDMs. dATP
and dGTP concentrations (Figures 1D and 1E) were
significantly increased, while dCTP and dTTP concentra-
tions (Figures 1F and 1G) were only modestly increased.
dGTP concentration peaked at day 1, consistent with
our published results [42]. Importantly, dATP peaked
at day 2 before the contraction began, indicating dNTP
modulation was different for each of the nucleotides.
The dNTP contraction occurred even though SAMHD1
protein remained undetectable at days 3–5 by Western
blot analysis. Basically, the rapid dNTP retraction fol-
lowing its acute elevation by Vpx occurred much ahead
of the SAMHD1 recovery. These data suggest that the
decrease in dNTP levels may be independent of the
total SAMHD1 protein level due to various possibilities,
which are discussed below.
Effect of dual Vpx + VLP treatment on dNTP levels in MDMs
The day 7 time point after single Vpx + VLP treatment of
MDMs (Figure 1B) provided us with the unique oppor-
tunity to test whether dual (2×) Vpx + VLP treatment also
influences the dNTP concentrations when SAMHD1 was
less than 5% of the normal SAMHD1 level. For this test,
dual Vpx + VLP treatment was performed at day 7 post
primary VLP treatment and samples were collected every
24 h from days 7–14 (Additional file 1). We speculated
that the peak in dNTP production during the dual
Vpx + VLP treatment could have been missed while
conducting kinetics analysis at 24 h time points. There-
fore, as depicted in Figure 2A, we performed tighter acute
kinetic dNTP analysis starting at day 7 after the dual
Vpx + VLP treatment in the MDMs and looking within
Figure 1 Analysis of single VLP treatment in MDMs. (A) MDMs were treated with Vpx- or Vpx + VLPs starting at day 0 and cell lysates were collected
every 24 h until day 14. Immunoblots were probed for SAMHD1 or GAPDH, loading control. One representative MDM donor of three is displayed.
(B) Quantitation of SAMHD1 expression (20 μg) by Western blot analysis is shown for the three independent MDM donors. Data are graphed by setting
SAMHD1 expression level at day 0 to 100%. Two-way ANOVA was done with Bonferroni post-test analysis to determine significance, *** = P < 0.001;
** = P < 0.01. (C) Western blot analysis using 60 μg total protein, 3× loading as compared to (B). SAMHD1 level of expression is below 3% even with
greater loading. (D-G) HIV RT-based dNTP assay was used to determine the levels of dATP (D), dGTP (E), dCTP (F) and dTTP (G). Data are graphed for the
15 days that the samples were collected. Two-way ANOVA analysis was performed and significant differences denoted on the graphs for dATP and dGTP.
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Figure 2 Faster rise in dNTPs after dual Vpx + VLP treatment in MDMs. (A) Diagram illustrating the experimental design. MDMs were treated
with VLP on days 0 and 7, which were followed by cell collection for dNTPs over the next 48 h. (B-E) Analysis of dNTP concentrations using the
RT-based assay. Significant differences in dATP (B) and dGTP (C) concentrations are shown when comparing the 2× Vpx- VLPs (yellow bars) and
2× Vpx + VLP (red bars) groups at 0, 1, 2, 4, 8, 12, 24, and 48 h post VLP addition. dATP (A) and dGTP (B) show a peak at 8 h after VLP addition,
while dCTP (C) and dTTP (D) appeared to peak 1–2 h after addition. Significant differences were determined first using one-way ANOVA, followed
by comparing each group using Mann–Whitney analysis. ***denotes P < 0.001.
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the second Vpx + VLP treatment showed an accelerated
dNTP enhancement that peaked at around 8 h for dATP
(Figure 2B) and dGTP (Figure 2C). Even more surpris-
ingly, dCTP (Figure 2D) and dTTP (Figure 2E) peaked at1–2 h post VLP treatment. Basically, the dual Vpx + VLP
treated MDMs produced an accelerated increase in dNTP
concentrations as compared to the single Vpx + VLP treat-
ment [42]. Several possible scenarios may explain the
faster dNTP elevation induced by the second Vpx + VLP
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SAMHD1 degradation, we speculate that Vpx may also
activate the overall dNTP biosynthesis pathways. Alter-
natively, ribonucleotide reductase (RNR) activity through
feedback modulation by cellular dATP was somehow chan-
ged from the primary and second Vpx +VLP treatment.
This would help account for the fairly rapid contraction
in dNTP concentrations after the second Vpx + VLP
treatment. We did not see any modulation in the subunits
of RNR after Vpx + VLP treatment (Additional file 2),
but we have not been able to rule out Vpx potential
modulation of RNR activity by an unknown mechanism.
Another potential mechanism is that Vpx may target a
putative minor SAMHD1 population that may be phos-
phorylated. Preliminary data suggest that MDMs can
have a pSAMHD1 at T592 population, but both time in
culture and SAMHD1 protein recovery after Vpx + VLP
treatment showed the loss and the lack of phosphorylated
SAMHD1, respectively (Additional file 3). This rules
out modulation of dNTP concentrations by SAMHD1
phosphorylation during the recovery phase of SAMHD1
(days 7–14).Comparison of the effects of the single and dual Vpx + VLP
treatments on HIV-1 transduction efficiency in MDMs
Next, we investigated how single and dual Vpx + VLP
treatments affects HIV-1 transduction in MDMs. For
this, we employed D3HIV-GFP vector that encodes the
entire HIV-1 genome except for env and nef, which are
deleted and replaced with eGFP. As shown in Figure 3A,
single VLP treatment and D3HIV-GFP vector was added
to the medium at day 0, followed by collection of the
MDMs at days 1, 2 and 7 for FACS analysis. As illustrated
in Figure 3B, MDMs were treated at days 0 and 7 with
VLPs, and then D3HIV-GFP vector was added at day 7.
MDMs were collected at days 8, 9 and 14 (corresponding
to days 1, 2 and 7 after D3HIV-GFP vector addition).
The vector transduction efficiency was measured by
monitoring eGFP expression by FACS analysis from two
independent MDM donors and graphed at days 1, 2 and 7
post D3HIV-GFP vector transduction (Figures 3C and
3D). MDMs treated with Vpx- VLP and D3HIV-GFP had
about 5% transduction at day 7 post transduction (see
white bars in Figure 3C and 3D). The single Vpx + VLP
treatment (black bars in Figure 3C and 3D) enhanced
HIV-1 vector transduction to ~30% transduction at day 7
as compared to the Vpx- VLP treatment (~5% at day 7).
However, the dual Vpx + VLP treatment (red bars) was
able to induce 50-60% transduction at day 7 as compared
to the single Vpx + VLP treatment (black bars). Collect-
ively, these data support that the faster dNTP increase by
the dual Vpx + VLP treatment was able to further enhance
HIV-1 transduction in MDMs.Measurement of dNTP intermediate metabolites by
quantitative LC-MS/MS
The overall dNTP biosynthesis pathways has more inter-
mediates than what our HIV RT-based dNTP assay can
measure. Since we observed a faster dNTP elevation by
the dual Vpx + VLP treatment as compared to the single
Vpx + VLP treatment (Figure 2), and that the rapid dNTP
retraction observed before any detectable SAMHD1
reappears (Figure 1), we monitored the metabolic changes
in all three dNTP intermediate precursors: deoxynucleoside
monophosphates (dNMPs) and diphosphates (dNDPs) and
triphosphates (dNTPs) metabolites, by employing quantita-
tive LC-MS/MS technology [45]. For these studies MDMs
were treated with either single VLP doses and cells
were harvested for dNTPs 24 h later. For the dNTP
levels (Figure 4A), it is clear that the single Vpx + VLP
treatment enhances the levels of and at least dADP,
dGDP and dCDP, while dTDP was below the level of
detection (see # in Figure 4B). But the dual Vpx + VLP
treatment (Figure 4D-F) also induced greater dNDP
levels, particularly purine dNDP as compared to the
same MDM donor treated with Vpx- VLP. For dNMPs
levels, only the dAMP measurement generated significantly
detectable signals in both single Vpx + VLP (Figure 4C)
and dual Vpx + VLP (Figure 4F) treatments in MDMs.
Importantly, the LC-MS/MS analysis supports that Vpx
+ VLP treatment not only elevates the dNTP levels in
MDMs but also the dNTP intermediate precursors.
Since the medium lacks deoxyribonucleosides, we pos-
tulate via indirect evidence that the increase in dNDP
metabolites has to occur through the activation of
RNR. The exact mechanism remains unclear and is not
linked to an increase in RNR subunit protein levels
(Additional file 2). Moreover, Vpx is localized to the
nucleus [5,10,14-19], suggesting that it does not have a
direct interaction with RNR.
Effect of gemcitabine, an RNR inhibitor, on the
Vpx-mediated dNTP elevation in MDMs
It was previously demonstrated that hydroxyurea, an RNR
inhibitor, could block Vpx-mediated increase in dNTPs
[41]. We examined the contribution of RNR to increase
the dNTP concentrations after Vpx-mediated SAMHD1
degradation in MDMs. We first tested dose-escalating
concentrations of gemcitabine, a clinically available RNR
inhibitor [46], for 24 h (Additional file 4). From these data,
we tested 40 and 100 nM dose-escalating concentrations
of gemcitabine. MDMs were pretreated 22.5 h with VLPs
before adding gemcitabine. Cells were collected 1.5 h later
and analyzed for changes in dNTP levels (Figure 5). We
observe a 50% reduction in the levels of dATP (Figure 5A),
dGTP (Figure 5B) and dCTP (Figure 5C) after 100 nM
gemcitabine treatments, whereas dTTP concentration
(Figure 5D) was less influenced. Collectively, these data
Figure 3 Faster transduction in dual Vpx + VLP treated MDMs. (A) Diagram showing the experimental procedure for single VLP treatment
of MDMs. VLP and D3HIV treatments occurred at day 0, followed by collecting the cells for FACS analysis at days 1, 2 and 7. (B) An illustration
depicting the experimental design with the dual VLP treatments occurring at days 0 and 7. D3HIV treatment was done at day 7. Cells were
collected at days 8, 9 and 14, corresponding to days 1, 2 and 7, respectively, after D3HIV vector addition to the medium. (C-D) FACS analysis
monitoring the frequency of GFP +MDMs for two independent donors treated with single VLP: Vpx- (white bars), Vpx + (black bars) or dual VLP:
Vpx- (yellow bars) and Vpx + (red bars). Significant differences were determined first using one-way ANOVA, followed by comparing each group using
Mann–Whitney analysis. ***denotes P < 0.001.
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crease in Vpx-mediated dNTPs increase in the absence
of SAMHD1.
Discussion
This investigation began by examining how quickly
SAMHD1 protein levels return after a single Vpx + VLP
treatment in seven day maturated, primary human
MDMs. We found that the level of SAMHD1 remained
very low (less than 3% of the normal level in macro-
phages) between days 1–6 before it became consistently
detectable by Western blot analysis at day 7. Vpx has
been shown to have a long cellular half-life [6] and
should be degraded roughly by day 5 after VLP treatment.
However, SAMHD1 never recovered to its normal high
level even at day 14, suggesting de novo protein synthesis
of SAMHD1 may also be very slow or negatively regulated
after Vpx treatment. Examining dNTP levels over thislong time course showed a different observation. The
levels of dNTPs were reduced well before the detection of
SAMHD1 level by Western blot (Figure 1A), yet dNTPs
declined starting at day 2 for dGTP, dCTP and dTTP
and day 3 for dATP post Vpx + VLP treatment. Thus
we speculate that additional factors or very low levels
of SAMHD1 may be regulating dNTP pool sizes. We
expected that the reduced level of SAMHD1 at day 7
post Vpx + VLP treatment would provide a window of
opportunity to investigate cellular dNTP metabolism
during a second Vpx + VLP exposure. Indeed, the dual
Vpx + VLP treatment of MDMs at day 7 was able to
display the same robust dNTP elevation at the time
point when SAMHD1 remained less than 3% of the
normal level in MDMs (Figure 2). We speculate that
since the kinetics of the dual treatment are faster and
the HLPC-MS data indicated an increase in dNDP
metabolites, Vpx may harbor a SAMHD1 independent
Figure 4 LC-MS/MS analysis of single and dual VLP treated MDMs. MDM donors were treated with a single or dual VLP. Cellular lysates were
analyzed by LC-MS/MS analysis. Fold changes in deoxynucleoside metabolites (A) dNTPs, (B) dNDP, and (C) dNMP, are plotted for the single VLP
treatment for two MDM donors. # denotes metabolites below the level of detection for LC-MS/MS analysis. Filled circles indicate metabolites that
could not be accurately determined due to overlaying peaks with another unidentified metabolite. Three MDM donors treated with dual VLP
have fold changes plotted (D) dNTP, (E) dNDP, and (F) dNMP levels.
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metabolism and elevates cellular dNTP levels in the pres-
ence of only 3% of the normal SAMHD1 level. This
potential mechanism is not related to the up regulations
of RNR subunits (Additional file 2). Moreover, we have no
direct evidence that Vpx interacts with any of the RNRsubunits. Thus, it remains unclear as to just how Vpx VLP
treatment and dNDP increase might be occurring.
Interestingly, the deoxypurine triphosphate (dATP
and dGTP) concentrations remained high for several
days after the single VLP treatment, while deoxypyri-
midines – dCTP and dTTP concentrations showed
Figure 5 Acute exposure of gemcitabine inhibits the further raise of dNTPs in single Vpx + VLP MDMs. To further validate that gemcitabine
does not have off target effects, MDMs were first treated with VLPs for 22.5 h before the addition of 40 and 100 nM gemcitabine to the medium.
Samples were processed for dNTPs 1.5 h after gemcitabine addition. (A) dATP, (B) dGTP, (C) dCTP, and (D) dTTP concentrations were determined
and means for two independent MDM donors plotted. Two-way ANOVA analysis was performed and significant differences denoted on the graphs.
Importantly, acute exposure of gemcitabine for 1.5 h caused a much greater inhibition in the further raise of dCTP, dGTP and dATP levels treatment as
compared to no gemcitabine control sample, while only having a modest influence on dTTP pool size.
Hollenbaugh et al. Retrovirology 2014, 11:63 Page 8 of 12
http://www.retrovirology.com/content/11/1/63only a transient increase before returning to base line
levels for the majority of the MDM donors tested in
this study (Figures 1E-F). Our data are consistent with
the recently generated SAMHD1 deficient mouse [5],
which shows that dATP and dGTP concentrations
were significantly increased in the SAMHD1 deficient
mice as compared to wild type mice. Importantly, the
dual Vpx + VLP treatment of MDMs was informative by
showing that the peak of the dATP and dGTP occurred
around 8 h post Vpx + VLP addition, which is much faster
than our results published for dGTP on the acute kinetics
by the single Vpx + VLP treatment [42]. Interestingly, we
observed a decline in the levels of all dNTPs at day 3 post
Vpx + VLP treatment, suggesting that turnover of the
dNTP pool occurs by other underlying mechanisms other
than SAMHD1. These other mechanisms may include
hydrolysis by deoxynucleoside diphosphatases [47,48],
shut-off of RNR activity, or conversion to energy currency
for other cellular enzyme reactions. Since MDMs are
non-dividing cells, we can rule out that the decrease in
dNTPs after a dual Vpx + VLP treatment is due to the
dNTP utilization during DNA replication. However, we
cannot rule out that DNA repair activity is occurringand is consuming the dNTPs. We postulate that the
elimination of SAMHD1 may lead to establishing a new
modulation set point of dNTP pools within the cell,
with dATP and dGTP concentrations remaining much
higher than dCTP and dTTP levels [5].
Conclusions
We employed a series of biochemical and virological
investigations with extensive and multiple exposures
of Vpx + VLP treatments to human primary MDMs.
These studies revealed that there was a significant
quantitative discord between levels of total SAMHD1
protein and cellular dNTPs when MDMs were treated
with Vpx + VLP. One potential explanation is that Vpx
may promote targeting of SAMHD1 for degradation
but also facilitate dNTP biosynthesis in macrophages
since we detect an increase in dNDP metabolites, which
are the precursors for dNTPs. This in turn would achieve
a rapid and robust dNTP elevation, which is necessary for
accelerating lentiviral reverse transcription for HIV-2
and SIV and also DNA gap-filling repair as part of
lentiviral integration [49], in cells having extremely low
cellular dNTP abundance.
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Ethics statement
These experiments used primary human monocytes
obtained from human buffy coats (New York Blood
Services, Long Island, NY). These are pre-existing materials
that are publicly available, and there is no subject-
identifying information associated with the material
obtained from this supplier. As such, the use of these
samples does not represent human subjects research
because: 1) materials were not collected specifically for
this study, and 2) we are not able to identify the subjects.
Cells
Primary human monocytes were isolated from the periph-
eral blood buffy coats by positive selection using MACS
CD14+ beads as previously described [50]. Monocytes
were maturated into monocyte-derived macrophages
(MDMs) in the presence of 5 ng/ml hGM-CSF (Miltenyl
Biotec) treated at days 0 and 2 of maturation. MDMs were
used at day 7 of maturation for experiments.
Primer extension assay
Protocol was followed as previously described [42]. MDMs
were lysed with 60% cold methanol. Cellular debris was
cleared by 14 K rpm centrifugation. Supernatant was
dried using a SpeedVac (Thermo Scientific). Pellets were
resuspended in 20 μl water. Two microliters of sample
were used in the primer extension assay. 5’ 32P-end-
labeled primer (“P”; 5’-GTCCCTCTTCGGGCGCCA-3’)
was individually annealed to one of four different
templates (3‘-CAGGGAGAAGCCCGCGGTN-5’). The
template:primer complex was extended by HIV-1 reverse
transcriptase, generating one additional nucleotide exten-
sion product (“P + 1”) for one of four dNTPs contained
in the dNTP samples extracted form the cells. In this
assay, the molar amount of the P + 1 product is equal
to that of each dNTP contained in the extracted samples,
which allows us to calculate and compare the dNTP
concentrations for the different treatments [44].
VLP generation
T225 flasks containing 293FT cells were transfected with
40 μg of pVpx- VLP or pVpx + VLP (kindly provided by
Drs. Florence Margottin-Goguet and Nathaniel Landau)
and 20 μg of pVSVg at a ratio of 1 μg of DNA to 3 μl of
polyethylenimine (1 mg/ml). The following day, medium
was discarded and replaced with fresh DMEM medium
(5% FBS and antibiotics). On days 2–3 after transfection,
the medium was collected and replaced with fresh
medium. On the day of collection, medium was centrifuged
at 1200 rpm for 5 min to remove cells. Supernatant
was subsequently filtered through a 0.45-μm membrane
(Corning Inc.) and overlaid on top of 5 ml of a 25%
sucrose cushion (25% (w/v) sucrose, 10 mM Tris–HCl[pH 7.5], 0.1 M NaCl and 1 mM EDTA). VLPs were
concentrated at 28,000 rpm for 90 min by ultracentrifu-
gation. Supernatant was aspirated, and pellets were
resuspended in 600 μl of serum-free DMEM. Supernatant
was centrifuged for 1 min at 14 K rpm to remove debris.
Aliquots (50 μl) were stored at −80°C. The p27 antigen
level was determined using an ELISA kit (Advanced Bio-
Science Laboratories, Inc., Rockville MD). A minimum of
145 ng of p27/million cells was used in experiments.
D3HIV-GFP generation
pD3HIV-GFP vector encodes the HIV-1 NL4-3 genome
with the eGFP gene in place of the HIV-1 nef gene and
has a deleted envelope gene [44]. To generate virus,
293FT cells in T225 flasks were transfected with 60 μg
pD3HIV-GFP and 20 μg pVSV-g using 140 μl polyethye-
nimine (1 mg/ml) in 37 ml DMEM medium/flask. At
day 1 of HIV-1 production, medium was discarded and
replaced with fresh complete DMEM medium (5% FBS
plus antibiotics). At day 2, the medium was harvested
and replaced. The medium was centrifuged at 2500 rpm
for 7 min to remove cellular debris, and then stored at 4°C
in T75 flask. Day 3 medium was harvested and processed
as described for day 2. D3HIV-GFP was concentrated
using ultracentrifugation (22 K rpm for 2 h in a SW32 Ti
rotor). Pellets were resuspended in 0.5 ml serum free
DMEM medium. Afterwards, debris was removed by cen-
trifugation (14 K for 2 min). Sample aliquots (50 μl) were
frozen at −80°C until used. MDMs were transduced with
D3HIV-GFP and then the samples were analyzed using
Accuri C6 flow cytometer monitoring GFP expression at
the indicated times. Data files were analyzed using FlowJo
software (TreeStar).
Mass spectrometry
MDM extracts were generated by scraping wells with
70% methanol and freezing them overnight at −80°C.
Extracts were centrifuged at 13,000 × g for 3 min and the
supernatants were subsequently dried. The resulting
samples were reconstituted in HPLC mobile phase for
LC-MS/MS analysis as described previously [51]. In
short, samples were reconstituted in 200 μl of 2 mM
NH4H2PO4 with 3 mM hexylamine then analyzed for deox-
yribonucleosides. Samples were separated using Hypersil
Gold 100 × 1 mm column using Mobile phase - A: aceto-
nitrile and B: 2 mM NH4H2PO4 with 3 mM hexylamine. A
increased from 5% to 50% in 10 min, keep 50% for 3 min.
The m/z parent to product MS/MS transitions: 523 to 146,
539 to 162, 496 to 119, and 495 to 81 were applied for the
standard stable labeled isotopes and 508 to 136, 524 to 152,
484 to 112, and 485 to 81 for the corresponding sample
nucleotides, respectively.
Samples were reconstituted in 200 μl of 2 mM
NH4H2PO4 with 3 mM hexylamine, and then split into
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nucleosides. Samples were separated using Hypersil
Gold 100 × 1 mm column using Mobile phase - A:
acetonitrile and B: 2 mM NH4H2PO4 with 3 mM hexy-
lamine. A increased from 5% to 50% in 10 min, keep
50% for 3 min. Instrument parameters were optimized
for each metabolite (Additional file 5).Western blot analysis
Samples were processed in RIPA buffer containing 1 μM
DTT, 10 μM PMSF, 10 μl/ml phosphatase inhibitor
(Sigma) and 10 μl/ml protease inhibitor (Sigma). The
cells were sonicated with 3×, 5 second pulses, to ensure
complete lysis. Cellular debris was removed by 15 K rpm
centrifugation for 10 min. Supernatants were stored
at −80°C before use. Cell lysates were resolved on a 8%
SDS-PAGE gel. Proteins were transferred to nitrocellulose
membrane and detected as described in the figure legends
using the following antibodies: rabbit anti-SAMHD1
mAb (Abcam), anti-GAPDH mouse mAb (Santa Cruz).
Anti-mouse and anti-rabbit secondary HRP antibodies
were purchased from GE HealthScience. HRP was detected
using chemiluminescent reagents (Pierce) following the
manufacturers instructions. Images were captured using
BioRad ChemiDoc Imager. Anti-pSAMHD1 T592 antibody
was obtained from Dr. Diaz-Griffero.Graphing and statistical analysis
Prism software was used for plotting the data. All the
data sets were compared for significant difference using
two-way ANOVA analysis and Bonferroni post-test analysis
for significance.Additional files
Additional file 1: Dual Vpx + VLP Kinetic Analysis. (A) Diagram
showing the treatment regime for single and dual VLP treatments and the
days harvested after treatment. (B-E) The HIV-1 RT-based dNTP assay was
performed on samples to determine concentrations of the four different
metabolites. Two-way- ANOVA was applied to determine significant
differences within each group indicated (*, P < 0.05; **, P < 0.01 and
***, P < 0.001). Analysis was done for two independent MDM donors.
Additional file 2: Analysis of RNR subunits. MDMs were treated with
VLP for 24 h and then processed for cellular lysates. Western blot analysis
was performed using 25 μg total protein to detect the major subunit, R1
(Abcam), or the small subunits R2 and p53R2 (Santa Cruz). No significant
changes in RNR expression levels were detected.
Additional file 3: Analysis of pSAMHD1 at 592. Two independent
MDM donors were examined for pSAMHD1 by immunoblot analysis
(20 μg protein). Total SAMHD1 was determined and GAPDH was used as
the internal loading control.
Additional file 4: Gencitabine inhibition of Vpx-mediated dNTP
increase. MDMs were pretreated for 2 h with various concentration of
gemcitabine as indicated in figures. Next, VLPs were added and cells were
placed in the incubator for 24 h, after which time they were processed for
dNTPs. The HIV-1 RT-based dNTP assay was done and data plotted for each
metabolite: (A) dATP, (B) dGTP, (C) dCTP and (D) dTTP. One-way ANOVA wasdone and significant differences indicated (*, P < 0.05; **, P < 0.01 and
***, P < 0.001). Analysis was done for two independent donors.
Additional file 5: HPLC-MS settings for instrument optimization.
Each metabolite was purchased from Sigma and then ran on the HLPC-MS
to optimize the reading. Then setting were then used to generate a
concentration curve that was applied to determine the concentrations
of these metabolites in MDMs treated with Vpx + VLP and Vpx- VLPs.
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